Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. The Massachusetts-based company said that third-quarter revenue from its Spikevax shot came in at $1.8 billion, with $1.2 …